CHALLENGES AND POLICY SUPPORTS IN INDONESIAN PHARMACEUTICAL RAW MATERIALS INDUSTRY

Hermawan, Erwan; Hadiyati, Nur Anis; Adiarso, Adiarso; Setiyadi, Ermawan Darma; Zunuraen, Siti; Hidayat, Dudi; Wahyudi, Anwar; Ru'yi, Hartini Ahadiyatur

doi:10.20473/jaki.v11i2.2023.196-211

Akses terbuka Jurnal SINTA 1

CHALLENGES AND POLICY SUPPORTS IN INDONESIAN PHARMACEUTICAL RAW MATERIALS INDUSTRY

Jurnal Administrasi Kesehatan Indonesia · Vol. 11 No. 2 (2023) · hlm. 196–211

DOI: 10.20473/jaki.v11i2.2023.196-211
ISSN: 2540-9301, 2303-3592
Terbit: 2023-11-09
Penerbit: Universitas Airlangga
Bahasa: eng
Lisensi: creativecommons.org/licenses/by-sa/4.0

Abstrak

Background: Indonesian pharmaceutical industry is experiencing many challenges, spesficically their raw materials mostly are imported products. Several factors that cause the pharmaceutical raw materials industry to be challenging are lack of mastery of technology, lack of government support, low budget for R&D, high costs of development and time consuming, and low innovation incentives. Aims: This study aims to conduct a study on the strategies for developing the pharmaceutical raw material industry in Indonesia Methods: This study employed a qualitative method, the data triangulation gathered from interviews and discussions with several industries and institutions. The study was conducted for six months in 2022. Results: The policies that are required to be implemented to make the pharmaceutical raw materials industry thrive are (i) the presence of a clear grand strategy, (ii) determining the priority of pharmaceutical raw materials based on industrial needs, (iii) protecting domestic products, (iv) increasing health spending, (v) strengthening basic chemical product, and (vi) increasing the budget for R&D. Conclusion: Some policies that can be enhanced include providing incentives and policies that favor the local pharmaceutical raw material industry, ranging from regulated prices, putting an end to dependence on imported products, tax incentives, domestic products protection through import tariff policies, energy subsidies, technology transfers, et cetera. Keywords: pharmaceutical raw materials, policy, pharmaceutical

Kata kunci

Jaringan kolaborasi para penulis

17 penulis · 59 tautan kepenulisan bersama

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

Afiliasi tidak diketahui

Organisasi berbeda
Organisasi sama
Afiliasi tidak diketahui
Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel

Tampilkan sebagai tabel

Rekan penulis	Organisasi	Artikel bersama
Heru Susanto	Afiliasi tidak diketahui	1
Arief Ameir Rahman Setiawan	Afiliasi tidak diketahui	1
Firman Tri Adjie	Afiliasi tidak diketahui	1
Hafiizh Prasetiya	Afiliasi tidak diketahui	1
Joddy Arya Laksmono	Afiliasi tidak diketahui	1
Anny Sulaswatty	Afiliasi tidak diketahui	1
Edi Iswanto Wiloso	Afiliasi tidak diketahui	1
Yudiartono Yudiartono	Afiliasi tidak diketahui	1
Jaka Windarta	Afiliasi tidak diketahui	1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://e-journal.unair.ac.id/JAKI/oai, pertama di-harvest 9 Nov 2026, terakhir terlihat 9 Nov 2026.

Metadata asli (oai_dc)

<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">CHALLENGES AND POLICY SUPPORTS IN INDONESIAN PHARMACEUTICAL RAW MATERIALS INDUSTRY</dc:title>
	<dc:creator>Hermawan, Erwan</dc:creator>
	<dc:creator>Hadiyati, Nur Anis</dc:creator>
	<dc:creator>Adiarso, Adiarso</dc:creator>
	<dc:creator>Setiyadi, Ermawan Darma</dc:creator>
	<dc:creator>Zunuraen, Siti</dc:creator>
	<dc:creator>Hidayat, Dudi</dc:creator>
	<dc:creator>Wahyudi, Anwar</dc:creator>
	<dc:creator>Ru'yi, Hartini Ahadiyatur</dc:creator>
	<dc:subject xml:lang="en-US">policy</dc:subject>
	<dc:subject xml:lang="en-US">pharmaceutical raw materials</dc:subject>
	<dc:subject xml:lang="en-US">pharmaceutical</dc:subject>
	<dc:subject xml:lang="en-US">pharmaceutical</dc:subject>
	<dc:subject xml:lang="en-US">policy</dc:subject>
	<dc:subject xml:lang="en-US">pharmaceutical raw materials</dc:subject>
	<dc:description xml:lang="en-US">Background: Indonesian pharmaceutical industry is experiencing many challenges, spesficically their raw materials mostly are imported products. Several factors that cause the pharmaceutical raw materials industry to be challenging are lack of mastery of technology, lack of government support, low budget for R&amp;amp;D, high costs of development and time consuming, and low innovation incentives.
Aims: This study aims to conduct a study on the strategies for developing the pharmaceutical raw material industry in Indonesia
Methods: This study employed a qualitative method, the data triangulation gathered from interviews and discussions with several industries and institutions. The study was conducted for six months in 2022.
Results: The policies that are required to be implemented to make the pharmaceutical raw materials industry thrive are (i) the presence of a clear grand strategy, (ii) determining the priority of pharmaceutical raw materials based on industrial needs, (iii) protecting domestic products, (iv) increasing health spending, (v) strengthening basic chemical product, and (vi) increasing the budget for R&amp;amp;D.
Conclusion: Some policies that can be enhanced include providing incentives and policies that favor the local pharmaceutical raw material industry, ranging from regulated prices, putting an end to dependence on imported products, tax incentives, domestic products protection through import tariff policies, energy subsidies, technology transfers, et cetera.
Keywords: pharmaceutical raw materials, policy, pharmaceutical</dc:description>
	<dc:publisher xml:lang="en-US">Universitas Airlangga</dc:publisher>
	<dc:date>2023-11-09</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US">Peer-Reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:format>text/xml</dc:format>
	<dc:identifier>https://e-journal.unair.ac.id/JAKI/article/view/45322</dc:identifier>
	<dc:identifier>10.20473/jaki.v11i2.2023.196-211</dc:identifier>
	<dc:source xml:lang="en-US">Indonesian Journal of Health Administration (Jurnal Administrasi Kesehatan Indonesia); Vol. 11 No. 2 (2023): December ; 196-211</dc:source>
	<dc:source>2540-9301</dc:source>
	<dc:source>2303-3592</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://e-journal.unair.ac.id/JAKI/article/view/45322/26636</dc:relation>
	<dc:relation>https://e-journal.unair.ac.id/JAKI/article/view/45322/27363</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2023 Erwan Hermawan, Nur Anis Hadiyati, Adiarso, Ermawan Darma Setiyadi, Siti Zunuraen, Dudi Hidayat, Anwar Wahyudi</dc:rights>
	<dc:rights xml:lang="en-US">https://creativecommons.org/licenses/by-sa/4.0</dc:rights>
</oai_dc:dc>